Focus on Ziprasidone

References

• Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA III, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther, 1995 275;1(Oct),101–13
   PubMed Web of Science ®Google Scholar
• Tandon R, Harrigan E, Zorn AH. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serot Res 1997;4:159–77
   Google Scholar
• Keck P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebocontrolled trial. Psychopharmacol 1998;140: 173–84
   PubMed Web of Science ®Google Scholar
• Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacol 1999;20(5):491–505
   PubMed Web of Science ®Google Scholar
• Swift RH, Harrigan EP, van Kammen DP. A comparison of fixed-dose, intramuscular (IM) ziprasidone with flexible dose, IM haloperidol. Eur Psych 1998;13(4):S304
   Google Scholar
• Reeves KR, Swift RH, Harrigan EP, Lesem M. Rapid acting, intramuscular ziprasidone 10 mg and 20 mg in patients with psychosis and acute agitation: results of two double-blind, randomized, fixed-does studies. Poster presentation (1998)
   Google Scholar
• Sprouse JS, Reynolds LS, Braselton JP, Rollema H, Zorn SH. Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacol 1999 21;5(Nov):622–31
   PubMed Web of Science ®Google Scholar
• Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet 1995;345:557–62
   PubMed Web of Science ®Google Scholar
• O’Connor R, Harrigan EP, Heym J, et al. The efficacy and safety profile of a new antipsychotic, ziprasidone. Presented at the Xth World Congress of Psychiatry, Madrid, Spain 23–28 May, 1996
   Google Scholar
• Miceli JJ, Wilner KD, Hansen RA, Johnson AC, Apseloff G, Gerber N. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol 2000;49(Suppl 1):5S–13S
   PubMedGoogle Scholar
• Meltzer H, Arato M, O’Connor. Path analysis of the ZEUS study provides evidence of a direct effect of ziprasidone on primary negative symptoms in chronic, stable schizophrenia. Schizophr Res 2000;41(1 Spec Iss):B91
   Google Scholar
• Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman VM, Chappell PB. Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psych 2000;39(3, Mar):292–9
   PubMed Web of Science ®Google Scholar
• Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database of Systematic Reviews [computer file]. (2):CD000966, 2000
   Google Scholar
• Bagnall A, Lewis RA, Leitner ML, Kleijnen J. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews [computer file]. (2):CD001945, 2000
   Google Scholar
• Aweeka F, Jayesekara D, Horton M, Swan S, Lambrecht L, Wilner KD, Sherwood J, Anziano RJ, Smolarek TA, Turncliff RZ. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol 2000;49(Suppl 1):27S–33S
   Google Scholar
• Everson G, Lasseter KC, Anderson KE, Bauer LA, Carithens RL Jr, Wilner KD, Johnson A, Anziano RJ, Smolarek TA, Turncliff RZ. The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. Br J Clin Pharmacol 2000; 49(Suppl 1):21S–26S
   Google Scholar
• Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000;49(Suppl 1):35S–42S
   PubMedGoogle Scholar
• Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psych 1999;156(11):1686–96
   Google Scholar
• Taylor DM, McAskill R. Atypical antipsychotics and weight gain – a systematic review. Acta Psych Scand 2000;101(6):416–32
   PubMed Web of Science ®Google Scholar
• Apseloff G, Mullet D, Wilner KD, Anziano RJ, Tensfeldt TG, Pelletier SM, Gerber N. The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. Br J Clin Pharmacol 2000;49 (Suppl 1):61S–64S
   PubMedGoogle Scholar
• Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol 2000;49(Suppl 1):65S–70S
   Google Scholar
• Muirhead GJ, Harness J, Holt PR, Oliver S, Anziano RJ. Ziprasidone and the pharmacokinetics of a combined oral contraceptive. Br J Clin Pharmacol 2000;49(Suppl 1):49S–56S
   Google Scholar
• Wilner KD, Demattos SB, Anziano RJ, Apseloff G, Gerber N Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers. Br J Clin Pharmacol 2000;49(Suppl 1):43S–47S
   PubMedGoogle Scholar
• Brook S, Krams M, Gunn KP and the Zirprasidone IM Study Group. The efficacy and tolerability of intramuscular (IM) ziprasidone versus IM haloperidol in patients with acute, non-organic psychosis. Eur Psych 1998;13(4):S303
   Google Scholar
• Hagger C, Mitchell D, Wise AL, Schulz SC. Effects on oral ziprasidone and risperidone on cognitive functioning in patients with schizophrenia or schizoaffective disorder: preliminary data. Eur Neuropsychopharamacol 1997;7(Suppl 2):219
   PubMedGoogle Scholar
• Daniel D, Stern R, Kramer T and the Switch Study Group. Switching from olanzapine to ziprasidone: an interim analysis of a 6-week study. Presented at the 152nd APA, Washington, DC, 15–20 May, 1999
   Google Scholar
• Weiden P, Simpson G, Kramer T, Harvey P and the Switch Study Group (1999) Switching from conventional antipsychotics to ziprasidone: an interim analysis of a 6-week study. Presented at the 152nd APA, Washington, DC, 15–20 May, 1999
   Google Scholar